Vaso Corporation (VASO)

[ALERTS100%to10000%GAIN]

VASO~~over $20,000 ,000 +++ dollars cash flow in 2021,per CO

[ALERTS100%to10000%GAIN]

VASO~~looks great into next week, break chart here in little,
https://stockcharts.com/freecharts/gallery.html?vaso

[ALERTS100%to10000%GAIN]

VASO~~hugee,positive cashflow of $5.5 million from operating activities in the first three months of 2021

VASO~~MONSTA HUGEE,"The Company also generated positive cashflow of [color=red]$5.5 million [/green]from operating activities in the first three months of 2021, and continues to maintain a strong cash position even after a significant amount of debt paydown. As the country starts to reopen post-pandemic, we currently expect to see in the coming periods a recovery in our top-line performance and a more profitable bottom line," concluded Dr. Ma.

[Golden Cross]

Looks like its found a bottom here

[ALERTS100%to10000%GAIN]

VASO gonna run nicely, Results for VASO

Elder Bar Turned Green
P&F Double Bottom Breakout
P&F Triple Bottom Breakdown

[ALERTS100%to10000%GAIN]

The Company also generated [color=red]positive cashflow of $5.5 million[/green] from operating activities in the first three months of 2021

[ALERTS100%to10000%GAIN]

VASO~~MONSTA HUGEE,"The Company also generated positive cashflow of $5.5 million from operating activities in the first three months of 2021, and continues to maintain a strong cash position even after a significant amount of debt paydown. As the country starts to reopen post-pandemic, we currently expect to see in the coming periods a recovery in our top-line performance and a more profitable bottom line," concluded Dr. Ma.

[ALERTS100%to10000%GAIN]

"I am excited to report that, while we customarily experience an operating loss in the first quarter of the year due to the seasonal nature of our businesses, all three of our business segments - IT, professional sales service and equipment - delivered continued improvement in operating results in the first quarter of 2021, with the IT and equipment segments actually achieving operating profitability," Dr. Ma continued.

[ALERTS100%to10000%GAIN]

"For the first quarter of 2021, the Company recorded total revenue of $16.5 million, a 4% decrease year-over-year," commented Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. "Nonetheless, our quarterly operating loss was significantly reduced, from $1.4 million to $539 thousand when compared to the same quarter last year, largely a result of substantially increased operating efficiency

[ALERTS100%to10000%GAIN]

Vaso Corporation Announces Financial Results for First Quarter 2021
Jun. 04, 2021 9:00 AM ETAccesswireVaso Corporation (VASO)
The Company Reports Continued Improvement in All Business Segments

PLAINVIEW, NY / ACCESSWIRE / June 4, 2021 / Vaso Corporation (VASO) (OTCMKTS:VASO) today reported its operating results for the three months ended March 31, 2021.

"For the first quarter of 2021, the Company recorded total revenue of $16.5 million, a 4% decrease year-over-year," commented Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. "Nonetheless, our quarterly operating loss was significantly reduced, from $1.4 million to $539 thousand when compared to the same quarter last year, largely a result of substantially increased operating efficiency."

"I am excited to report that, while we customarily experience an operating loss in the first quarter of the year due to the seasonal nature of our businesses, all three of our business segments - IT, professional sales service and equipment - delivered continued improvement in operating results in the first quarter of 2021, with the IT and equipment segments actually achieving operating profitability," Dr. Ma continued.

"The Company also generated positive cashflow of $5.5 million from operating activities in the first three months of 2021, and continues to maintain a strong cash position even after a significant amount of debt paydown. As the country starts to reopen post-pandemic, we currently expect to see in the coming periods a recovery in our top-line performance and a more profitable bottom line," concluded Dr. Ma.

Financial Results for Three Months Ended March 31, 2021

For the three months ended March 31, 2021, revenue decreased by 4% to $16.5 million from $17.2 million for the same period of 2020, due primarily to the decrease of $511 thousand, or 10%, in revenue in our professional sales service segment as the result of lower equipment deliveries by our partner during the quarter. Revenue in our IT segment decreased by $30 thousand in the first quarter 2021 when compared to the same quarter of 2020; and our equipment segment revenue decreased by $167 thousand when compared to the first quarter of 2020, principally due to the deconsolidation of EECP operations in the financial statements for the first quarter of 2021 as a result of sale of equity in the EECP business in the second quarter of 2020.

Gross profit for the first quarter of 2021 decreased by $580 thousand, or 6%, to $8.6 million, compared with a gross profit of $9.1 million for the same quarter of 2020. This decrease was primarily the result of the decrease in revenue.

Selling, general and administrative (SG&A) expenses for the first quarter of 2021 decreased by $1.4 million, or 13%, to $9.0 million, compared to the first quarter of 2020. The decrease is primarily attributable to a decrease in personnel costs in the IT and equipment segments, and a decrease in SG&A costs in the professional sales service segment resulting from lower sales meeting and travel costs. SG&A expenses were 54% and 60% of revenue in the first quarter of 2021 and 2020, respectively.

Operating loss for the three months ended March 31, 2021 was $539 thousand, compared to an operating loss of $1.4 million in the first quarter 2020, representing an improvement of $821 thousand, or 60%, as operating costs decreased substantially more than gross profit, year-over-year.

Net loss for the three months ended March 31, 2021 was $643 thousand, a significant improvement over the loss of $1.5 million for the first quarter of 2020.

Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, and stock-based compensation) improved to a positive $101 thousand for the quarter, compared to a loss of $683 thousand in the first quarter of 2020.

Net cash provided by operating activities were $5.5 million and $6.3 million during the first quarter of 2021 and 2020, respectively. As of May 31, 2021, the Company's net cash was approximately $10.6 million.

About Vaso

Vaso Corporation is a diversified medical technology company with several distinctive but related specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for diagnostic imaging products; and design, manufacture and sale of proprietary medical devices.

The Company operates through three wholly owned subsidiaries:

VasoTechnology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of Radiology Information System ("RIS"), Picture Archiving and Communication System ("PACS"), and other software solutions from various vendors as well as related services, including implementation, management and support; and NetWolves Network Services LLC, a managed network services provider with an extensive, proprietary service platform to a broad base of customers.
Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare (GHCI) diagnostic imaging products in certain market segments in the USA.
VasoMedical, Inc. manages and coordinates the design, manufacture and sales of proprietary medical equipment and software, as well as operates the Company's overseas assets including China-based subsidiaries.
Additional information is available on the Company's website at www.vasocorporation.com.

[Golden Cross]

VASO Now Pink Current
https://www.otcmarkets.com/stock/VASO/disclosure

[bobkubecka]

VASO
https://www.otcmarkets.com/stock/VASO/news/story?e&id=1884845
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2020
The Company Reports Improved Profitability Despite Pandemic

PLAINVIEW, NY / ACCESSWIRE / May 4, 2021 / Vaso Corporation ("Vaso") (OTC PINK:VASO) today reported its operating results for the three months and year ended December 31, 2020.

"The Company was able to conclude a profitable year in 2020 as it experienced an unprecedented impact of the economic shutdown due to the pandemic," commented Dr. Jun Ma, President and CEO of the Company. "Specifically, net income for fiscal year 2020 was $358 thousand, compared to a net loss of $382 thousand in the prior year, although revenue for the year decreased by $5.7 million to $69.9 million."

"The much-improved profitability was primarily the result of significant cost reductions. Selling, general and administrative costs went down by $4.0 million, or 9.7%, in 2020 when compared to 2019," Dr. Ma continued. "In addition, the Company generated $5.9 million from operating activities in the year 2020 and its cash position remains strong."

"As the country starts to get back to normalcy, we'll continue to exercise our diligence in executing our strategy and look to further improve performance of all our business units," concluded Dr. Ma.

The following financial results for the three and twelve months ended December 31, 2019 have been revised for the correction of errors.

Financial Results for Three Months Ended December 31, 2020
For the three months ended December 31, 2020, revenue decreased by 21.2% to $18.7 million from $23.7 million for the same period of 2019, due primarily to the decrease of $4.1 million, or 36.6%, in revenue in our professional sales service segment as the result of lower deliveries by our partner of underlying equipment during the quarter. Revenue in our IT segment decreased 3.4%, to $10.9 million in the fourth quarter 2020, compared to the same quarter of 2019, while our equipment segment revenue decreased 44.5% to $614 thousand from $1.1 million for the fourth quarter of 2019, due to the deconsolidation of EECP business as the result of the sale of equity in the EECP business early in the year, offset by an increase in sales in our Biox products.

Gross profit for the fourth quarter of 2020 decreased by 22.5% to $11.1 million, compared with a gross profit of $14.3 million for the same quarter of 2019. This decrease was primarily the result of the decrease in revenue in the professional sales service and IT segments.

Selling, general and administrative (SG&A) expenses for the fourth quarter of 2020 decreased by 14.1% to $9.6 million, compared to $11.1 million for the fourth quarter of 2019. The decrease was primarily attributable to a decrease in personnel costs in the IT segment and other cost reductions. SG&A expenses were 51.2% and 47.0% of revenue in the fourth quarter of 2020 and 2019, respectively.

Net income for the three months ended December 31, 2020 was $1.2 million, compared with a net income of $2.7 million for the three months ended December 31, 2019.

Financial Results for Year Ended December 31, 2020
For the year ended December 31, 2020, revenue decreased by $5.7 million or 7.5% to $69.9 million when compared with $75.5 million for the year 2019. Revenue in our IT segment decreased 3.5% to $43.9 million for the year 2020, from 2019 revenue of $45.5 million, primarily due to a decrease of revenue in the healthcare IT business. Commission revenues in our professional sales service segment decreased by 12.8% to $22.9 million in the year 2020, compared to $26.2 million in 2019. The decrease was the result of lower equipment deliveries by our partner and lower blended commission rates for the equipment delivered during the year. Equipment segment revenue for the year 2020 decreased by 18.7% to $3.1 million, from $3.8 million in 2019, principally due to the sale of 51% of our EECP business early in the year, partially offset by an increase in sales in our China operations. Revenues in the IT and professional sales service segments were negatively impacted by the COVID-19 pandemic.

Gross profit for the year ended December 31, 2020 decreased 9.1% to $38.6 million, from $42.4 million in 2019, as a result of the lower sales in our IT and professional sales service segments.

SG&A expenses for the year ended December 31, 2020 decreased $4.0 million or 9.7% to $37.1 million, or 53.0% of revenue, compared with $41.0 million, or 54.3% of revenue, for the same period in 2019. The decrease resulted primarily from a decrease $3.1 million in personnel and travel costs in the professional sales service and IT segments, as well as a decrease in corporate expenses.

For the year ended December 31, 2020, the Company had net income of $358 thousand, compared with a net loss of $382 thousand for the year ended December 31, 2019.

Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, and share-based compensation) was $3.6 million for the year ended December 31, 2020 compared to Adjusted EBITDA of $3.5 million for the year ended December 31, 2019.

Net cash provided from operating activities in 2020 was $5.9 million, compared to net cash used in operating activities of $1.3 million in 2019. The increase is principally due to the increase in profitability and the decrease in accounts receivable. Net cash increased to $6.8 million at December 31, 2020, compared to $2.1 million at December 31, 2019. The increase in cash is the net effect of positive cash from operating activities, and proceeds of $3.6 million from a PPP loan, offset by the repayment of $1.2 million of the MedTech note and $1.4 million on our lines of credit. As of April 23, 2020, the Company's net cash was approximately $9.5 million.

Deferred revenue decreased to $17.7 million at December 31, 2020, compared to $19.3 million at December 31, 2019. The decrease is primarily the result of lower order bookings in the professional sales service segment. The deferred revenue will be recognized in the future when the underlying equipment or services are delivered and accepted at the customer site.

About Vaso
Vaso Corporation is a diversified medical technology company with several distinctive but related specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for diagnostic imaging products; and design, manufacture and sale of proprietary medical devices.

The Company operates through three wholly owned subsidiaries:

VasoTechnology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of Radiology Information System ("RIS"), Picture Archiving and Communication System ("PACS"), and other software solutions from various vendors as well as related services, including implementation, management and support; and NetWolves Network Services LLC, a managed network services provider with an extensive, proprietary service platform to a broad base of customers.
Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments in the USA.
VasoMedical, Inc. manages and coordinates the design, manufacture and sales of proprietary medical equipment and software, as well as operates the Company's overseas assets including China-based subsidiaries.
Additional information is available on the Company's website at www.vasocorporation.com.

Summarized Financial Information

FOR THE THREE MONTHS ENDED FOR THE YEAR ENDED
STATEMENTS OF OPERATIONS
December 31, 2020 December 31, 2019* December 31, 2020 December 31, 2019*
(In thousands)
(Unaudited)
Revenue
$ 18,691 $ 23,721 $ 69,850 $ 75,515
Gross profit
11,076 14,293 38,571 42,432
Operating income
1,302 2,960 772 591
Other income (expense), net
(30 ) (243 ) (415 ) (862 )
Income (loss) before taxes
1,272 2,717 357 (271 )
Income tax benefit (expense)
(96 ) (62 ) 1 (111 )
Net income (loss)
1,176 2,655 358 (382 )
Income tax (benefit) expense
96 62 (1 ) 111
Interest (income) expense, net
129 251 675 962
Depreciation and amortization
601 657 2,462 2,681
Non-cash stock-based compensation
19 18 88 141
Adjusted EBITDA**
$ 2,021 $ 3,643 $ 3,582 $ 3,513
BALANCE SHEETS
December 31, 2020 December 31, 2019*
(In thousands)
Total current assets
$ 22,268 $ 24,059
Total assets
$ 50,376 $ 54,364
Total current liabilities
$ 31,699 $ 33,003
Total stockholders' equity
$ 5,085 $ 4,314
* restated
**Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization and non-cash stock-based compensation

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "optimistic", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the impact of the current COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contact:
Michael J. Beecher
Investor Relations
Phone: [phone]
Email: [e-mail]

SOURCE: Vaso Corporation



View source version on accesswire.com:
https://www.accesswire.com/644209/Vaso-Corporation-Announces-Financial-Results-for-Fourth-Quarter-and-Full-Year-of-2020

© Copyright 2021 ACCESSWIRE. All Rights Reserved.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings

Pink No Information
Delinquent SEC Reporting
Transfer Agent Verified

[stocktrademan]

VASO buy 0.089000

Darvas Box Breakout

https://vasocorporation.com/

https://finance.yahoo.com/quote/VASO/profile?p=VASO

https://www.barchart.com/stocks/quotes/VASO

https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=VASO




normal chart









log chart









normal chart








log chart

[thumper1]

whole lotta love....best to all.

[whytestocks]

Breaking News: $VASO Vaso Corporation Reports Financial Results for Third Quarter 2020

Net Profit for the Quarter Increased by 104% Year-over-Year PLAINVIEW, NY / ACCESSWIRE / November 13, 2020 / Vaso Corporation ("Vaso") (OTC PINK:VASO) today reported its operating results for the three months ended September 30, 2020. "Despite continued impediment to business by the ...

Got this from VASO - Vaso Corporation Reports Financial Results for Third Quarter 2020

[nycusa12]

Vaso Corporation Reports Financial Results for Third Quarter 2020
Friday, November 13, 2020 9:00 AM
Share this article now
Topic: Earnings
Net Profit for the Quarter Increased by 104% Year-over-Year

PLAINVIEW, NY / ACCESSWIRE / November 13, 2020 / Vaso Corporation ("Vaso") (OTC PINK:VASO) today reported its operating results for the three months ended September 30, 2020.

"Despite continued impediment to business by the COVID pandemic, which led to a 6% drop in quarterly revenue from a year ago, the Company recorded an operating income of $1.3 million for the third quarter of 2020, an increase of 56% when compared to the $0.8 million operating income for the same quarter last year. This is mainly a result of much lower selling, general and administrative ("SG&A") costs, which during the quarter decreased by 14% year-over-year," commented Dr. Jun Ma, President and CEO of the Company. "Net profit for the quarter was $1.1 million, representing an increase of 104% year-over-year. Year-to-date, we saw a $2.2 million improvement to the bottom line from the prior year even when the top line was slightly down. The Company has also generated $4.7 million cash from operating activities for the nine months ended September 30, 2020, and maintains a healthy cash position as of today."

"We remain cautiously optimistic about the current state of our businesses and are confident about the future of the Company. We are particularly encouraged by the performance of our professional sales service and equipment segments, which have shown significant improvements in the quarterly and year-to-date operating results even during this difficult year. We continue to be vigilant and stay ready for the recovery of the economy from the pandemic," concluded Dr. Ma.

Financial Results for Three Months Ended September 30, 2020

For the three months ended September 30, 2020, revenue decreased $1.2 million, or 6%, to $17.5 million from $18.7 million for the same period of 2019, primarily due to the impact of the COVID-19 pandemic. Quarterly revenue in our IT segment decreased by $652 thousand or 6% year-over-year as both the healthcare IT business and network services business were affected by the pandemic. Revenue in the professional sales service segment decreased by $535 thousand, or 8% year-over-year, mainly due to lower equipment deliveries by our partner. Revenue in the equipment segment decreased by $6 thousand, or 0.7% year-over-year, mainly due to exclusion of EECP sales in the reporting, offset by an increase in the Biox equipment sales.

Gross profit for the third quarter of 2020 decreased by 9% to $9.9 million, compared with a gross profit of $10.8 million for the third quarter of 2019. This decrease is primarily the result of a decrease in revenue in the IT and professional sales service segments due to the impact of the COVID-19 pandemic. In the IT segment gross profit decreased by $588 thousand or 12% year-over-year. Gross profit in the professional sales service segment decreased by $487 thousand or 9% year-over-year. Gross profit in the equipment segment increased $113 thousand, or 20% in the third quarter 2020 compared to the same period in 2019.

SG&A expenses for the third quarter of 2020 decreased by 14% to $8.5 million compared to $9.8 million for the same quarter of 2019. The decrease is primarily attributable to decreases in personnel and other costs in the IT segment and decreases in travel and related costs in the professional sales service and equipment segments.

Research and development costs decreased by 11% to $174 thousand in the third quarter of 2020 compared to the same period in 2019, primarily due to lower software development costs in the equipment segment.

Net income for the three months ended September 30, 2020 was $1.1 million, compared to net income of $562 thousand for the third quarter of 2019. The increase of $584 thousand, or 104%, is primarily the result of the decrease in SG&A costs offset by the lower gross profit.

Net cash provided by operating activities was $4.7 million in the nine months ended September 30, 2020, compared to net cash used in operating activities of $2.1 million for the same period in 2019. Cash and cash equivalents at September 30, 2020 was $6.9 million, compared to $2.1 million at December 31, 2019.

Total deferred revenue remains substantial, at approximately $16.7 million as of September 30, 2020, which will be recognized in the future when the underlying equipment or services are delivered and accepted at the customer site. Our shareholders' equity decreased to $5.3 million as of September 30, 2020 from $5.8 million as of December 31, 2019.

About Vaso

Vaso Corporation is a diversified medical technology company with several distinctive but related specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for diagnostic imaging products; and design, manufacture and sale of proprietary medical devices.

The Company operates through three wholly owned subsidiaries:

VasoTechnology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of Radiology Information System ("RIS"), Picture Archiving and Communication System ("PACS"), and other software solutions from various vendors as well as related services, including implementation, management and support; and NetWolves Network Services LLC, a managed network services provider with an extensive, proprietary service platform to a broad base of customers.
Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments in the USA.
VasoMedical, Inc. manages and coordinates the design, manufacture and sales of proprietary medical equipment and software, as well as operates the Company's overseas assets including China-based subsidiaries.
Additional information is available on the Company's website at www.vasocorporation.com.

Summarized Financial Information


FOR THE THREE MONTHS ENDED FOR THE NINE MONTHS ENDED
STATEMENTS OF OPERATIONS
September 30, 2020 September 30, 2019 September 30, 2020 September 30, 2019

(In thousands)


Revenue
$ 17,534 $ 18,727 $ 51,159 $ 51,794
Gross profit
9,879 10,841 27,495 28,139
Operating income (loss)
1,254 805 (530 ) (2,369 )
Other (expense) income, net
(97 ) (232 ) (385 ) (619 )
Income (loss) before taxes
1,157 573 (915 ) (2,988 )
Income tax (expense) benefit
(11 ) (11 ) 97 (49 )
Net income (loss)
$ 1,146 $ 562 $ (818 ) $ (3,037 )
Interest expense (income), net
133 268 546 711
Income tax expense (benefit)
11 11 (97 ) 49
Depreciation and amortization
610 679 1,861 2,024
Non-cash stock-based compensation
15 25 69 123
Adjusted EBITDA*
$ 1,915 $ 1,545 $ 1,561 $ (130 )


*Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization and non-cash stock-based compensation

BALANCE SHEETS
September 30, 2020 December 31, 2019

(In thousands)


Total current assets
$ 17,938 $ 24,059
Total assets
$ 46,582 $ 54,364
Total current liabilities
$ 30,890 $ 31,528
Total stockholders' equity
$ 5,267 $ 5,789


Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "optimistic", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the impact of the current COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contact:
Michael J. Beecher
Investor Relations
Phone: [phone]

Email: [e-mail]

SOURCE: Vaso Corporation

Vaso Corporation
Vaso Corporation
Exchange:
Ticker:
OTC PINK
VASO
$0.02
4.55%Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy | Terms and C

[mars001]

Getting better every ??????? The board has been quiet ?????

[Traderfan]

Getting better by the day here.

[otcbargains]

Market cap of under 7 mil. Most of this 3.6 mil will never have to be paid back.

[OBrien]

Lets add another $3.6Mil cash jeesh, Not long ago I was wondering if they would survive...

https://www.otcmarkets.com/filing/html?id=14077505&guid=6i1HUeCe4AeaE3h


On April 13, 2020, Registrant received funding of a $3,610,900 Note (the “Note”) issued by PNC Bank, National Association (“PNC”) pursuant to the Coronavirus Aid, Relief, and Economic Security (CARES) Act’s Paycheck Protection Program (the “Program”). Amounts outstanding on the Note are at the annual interest rate of 1%. During the first six months of the Note, there is no principal nor interest required to be paid. Thereafter, to the extent the Note is not forgiven under the Program, the outstanding balance of the Note converts to an amortizing term loan payable monthly over an eighteen month period. The Note can be prepaid at any time without penalty.

Registrant may apply to PNC for forgiveness of the Note in an amount equal to the sum of the following costs incurred by Registrant during the eight week period beginning on the date of first disbursement of the Note proceeds: (a) payroll costs; (b) any payment of interest on a covered mortgage obligation; (c) any covered rent payment; and (d) any covered utility payment. The amount of forgiveness is calculated in accordance with the requirements of the Program. In this regard, no more than 25% of the amount forgiven can be attributable to non-payroll costs.

[OBrien]

Yes, that $7M cash at end of Q1 is huge. They did pay down some debt this month so probably a bit lower now.
This could get MUCH higher very easily.


“Quote:
Subsequent Event

In April 2020, the Company extended the maturity dates of its lines of credit and MedTech Notes to April 30, 2021 and made principal payments aggregating $1.2 million on its lines of credit and $1.2 million on its MedTech Notes. The interest rate on the MedTech Notes was also reduced from 10% to 6% per annum. In addition, in March 2020 and April 2020 the maturity dates of $930 thousand in other related party notes was extended six months and the interest rate was reduced from 10% to 8% per annum.”

[Traderfan]

Yes based on Q3 I was buying some during the crisis in the last few weeks. For me it would be enough to already want to own it but obviously Q4 was a ton better and the cash number from Q1 is huge as well.

[OBrien]

Q3 was very good as well, coming in with $500k+ net income.
I’d have to go back and look but don’t remember them ever posting a profit in Q1. Shouldn’t be a long wait to see though.

[Traderfan]

Guess the market might want to wait for a second huge quarter, before it really takes off further who knows. Any dip from here and I will be a buyer for more shares. Q1 gonna be interesting. Let's see if there is follow through today.

[shurtha2000]

I remember buying this crap 20 years ago- how time Flies

[otcbargains]

I would think this is not only a safe haven but a hugely undervalued play. I guess we will find out.

[OBrien]

Yea, I am pretty surprised on the lack of volume. Maybe a delayed reaction the next few days?

[otcbargains]

This should have been up 1000% today on 200 mil in volume.

[OBrien]

It will be interesting to see if this results in a boost in deliveries of equipment. VASO sales a lot of CT and X-ray equipment...

https://www.americanmachinist.com/news/article/21126617/increasing-production-for-medical-equipment-ge-healthcare

[Stockbroken]

Congrats to fellow shareholders. They keep up the good work lately. Hopefully it can continue despite covid effects. Healthcare should be an OK sector to be in now and going forward.

[Traderfan]

It's at 037 so not sure how you come to this conclusion at this point lol.

[tiger3]

Looks like can't
hold at $0.03

[Traderfan]

Q1 numbers aren't too far away, I think this could have real legs over the next few weeks. Cash up to 7 million during Q1, hard to imagine that Q1 won't be another huge quarter.

[TrendTrade2016]

VASO on earnings...huge accumulation on the way down...classic...daytrade!

[OBrien]

My guess is this goes straight to .05 but will be interesting to see what it does from there

[OBrien]

.02 EPS between the last 2 quarters. Not sure why we couldn’t be over .10

[Traderfan]

Just saw the numbers from Q4. Pretty impressive. I bought a few shares lately during the massive sell off towards 015 and lower but will try to get a few more because this seems like a game changer to me, especially if you consider that their cash is up to 7 million in Q1. This could be a monster in the making if they can keep this up a few quarters.

[OBrien]

Just so much uncertainty now taken out of the stock that has been holding it down....

Subsequent Event

In April 2020, the Company extended the maturity dates of its lines of credit and MedTech Notes to April 30, 2021 and made principal payments aggregating $1.2 million on its lines of credit and $1.2 million on its MedTech Notes. The interest rate on the MedTech Notes was also reduced from 10% to 6% per annum. In addition, in March 2020 and April 2020 the maturity dates of $930 thousand in other related party notes was extended six months and the interest rate was reduced from 10% to 8% per annum.

[OBrien]

Hopefully, you are still holding?

[otcbargains]

I previously said I thought it could see mid to high .20's by the end of the year. I may have underestimated.

[OBrien]

VASO has had some big Qs in the past but when it was in the teens!
I was thinking somewhere between $1M-$2M in net income was possible but this was huge.
Not sure where the price goes here

[otcbargains]

I didn't expect this big of a q.

[OBrien]

Due to the impending maturity of such lines at the time of our previous quarterly filing on Form 10Q, we reported at that time that substantial doubt remained about our ability to continue as a going concern. In April 2020, we resolved the conditions that raised such substantial doubt by extending the maturity date of these lines of credit and another substantial debt to April 30, 2021.

[OBrien]

Huge Q4 and cash way up in Q1 2020...


“As of March 31, 2020, the Company's net cash was approximately $7.2 million.”

[OBrien]

Hell yea, Net Income of $3.1 for Q4!!

[nycusa12]

picked up 100k this morning ,,i hope we are near the bottom , GLTA

[mars001]

Thought that at one time Vaso was working with GE Health.

[OBrien]

Yea, potential is there but can they finally deliver?
.20/share would put be a lot closer to retirement!

[otcbargains]

Yeah it was finally breaking out and someone dumped. Probably have to wait for 4th q results to see more interest. Could see mid to high .20's by the end of the year if they can execute. IMO

[OBrien]

Bought back the rest at .026-.029.
This could get a HUGE bounce if they continue improvement and show a good Q4.